Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

Jade Biosciences, Inc. - Common Stock (NQ:JBIO)

21.82 -0.08 (-0.37%)

Streaming Delayed Price Updated: 1:51 PM EDT, Jun 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	494,122
Open	22.00
Bid (Size)	21.79 (100)
Ask (Size)	21.85 (200)
Prev. Close	21.90
Today's Range	21.53 - 22.11
52wk Range	6.670 - 28.00
Shares Outstanding	28,985,019
Dividend Yield	11.00%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 05, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces Pricing of Public Offering of Common Stock

June 03, 2026

From Jade Biosciences

Via GlobeNewswire

Performance

YTD	+54.1%	+54.1%
1 Month	+0.5%	+0.5%
3 Month	+56.4%	+56.4%
6 Month	+32.0%	+32.0%
1 Year	+108.2%	+108.2%

More News

Jade Biosciences Announces Proposed Underwritten Public Offering

June 03, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials ↗

June 01, 2026

Via MarketBeat

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

June 01, 2026

From Jade Biosciences

Via GlobeNewswire

What's going on in today's after hours session ↗

May 29, 2026

Via Chartmill

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

May 29, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

May 26, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

May 26, 2026

From Jade Biosciences

Via GlobeNewswire

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗

May 13, 2026

Via The Motley Fool

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗

May 13, 2026

Via The Motley Fool

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗

May 13, 2026

Via The Motley Fool

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 07, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 23, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

April 22, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 06, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Participate in Upcoming Conferences

February 11, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces $45 Million Private Placement

December 15, 2025

From Jade Biosciences

Via GlobeNewswire

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

November 08, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Participate in Upcoming Conferences

November 03, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

October 17, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

October 07, 2025

From Jade Biosciences

Via GlobeNewswire

Frequently Asked Questions

Is Jade Biosciences, Inc. - Common Stock publicly traded?

Yes, Jade Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Jade Biosciences, Inc. - Common Stock trade on?

Jade Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jade Biosciences, Inc. - Common Stock?

The ticker symbol for Jade Biosciences, Inc. - Common Stock is JBIO on the Nasdaq Stock Market

What is the current price of Jade Biosciences, Inc. - Common Stock?

The current price of Jade Biosciences, Inc. - Common Stock is 21.82

When was Jade Biosciences, Inc. - Common Stock last traded?

The last trade of Jade Biosciences, Inc. - Common Stock was at 06/25/26 01:51 PM ET

What is the market capitalization of Jade Biosciences, Inc. - Common Stock?

The market capitalization of Jade Biosciences, Inc. - Common Stock is 632.45M

How many shares of Jade Biosciences, Inc. - Common Stock are outstanding?

Jade Biosciences, Inc. - Common Stock has 632M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.